Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference
03 Juin 2022 - 5:45PM
Saint-Herblain
(France), June
3,
2022 – Valneva
SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced that its senior management will present
and participate in 1-on-1 meetings with institutional investors at
the Jefferies Healthcare Conference which will take place from June
8 to 10, 2022 in New York.
Valneva’s Chief Executive Officer Thomas
Lingelbach and Chief Financial Officer Peter Bühler will notably
discuss the Company’s late-stage vaccine candidates against Lyme
disease (VLA15), chikungunya (VLA1553) and COVID-19 (VLA2001).
Valneva was recently granted Conditional
Marketing Authorization in the United Kingdom for its inactivated
COVID-19 vaccine candidate VLA20011 and filed a Marketing
Authorization Application with the European Medicines in May
20222. The Company also recently commenced the pre-submission
process with the US Food and Drug Administration for its
single-shot chikungunya vaccine candidate VLA1553 after reporting
final positive pivotal Phase 3 results3 and lot-to-lot data4.
Additionally, in April 2022, Valneva and its partner Pfizer
reported first positive pediatric results for their Lyme disease
vaccine candidate VLA155. These positive data build on the strong
immunogenicity profile reported for adult participants (18-65 years
old) in February 2022, and the two companies expect to proceed with
a Phase 3 clinical trial in participants age 5-65, which is planned
to start in the third quarter of 2022.
The fireside chat at the Jefferies conference
will take place on June 9, 2022 at 11:30am EDT (17:30 CEST) and
will be accessible live via the following link,
https://wsw.com/webcast/jeff240/valn/1848225. A replay of the
webcast will be available following the live events in the
“Investor” section of the Valneva website at www.valneva.com.
To request a meeting at the event, please
contact your representative at Jefferies.
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development and then
applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to successfully
commercialize two vaccines and to rapidly advance a broad range of
vaccine candidates into and through the clinic, including
candidates against Lyme disease, the chikungunya virus and
COVID-19.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516
7099communications@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor RelationsM +001
917 815 4520joshua.drumm@valneva.com |
|
|
Forward-Looking StatementsThis
press release contains certain forward-looking statements relating
to the business of Valneva, including but not limited to the
initiation of clinical trials and product approvals. In addition,
even if the actual results or development of Valneva are consistent
with the forward-looking statements contained in this press
release, those results or developments of Valneva may not be
indicative of future results. In some cases, you can identify
forward-looking statements by words such as "could," "should,"
"may," "expects," "anticipates," "believes," "intends,"
"estimates," "aims," "targets," or similar words. These
forward-looking statements are based on the current expectations of
Valneva as of the date of this press release and are subject to a
number of known and unknown risks and uncertainties and other
factors that may cause actual results, performance or achievements
to be materially different from any future results, performance or
achievement expressed or implied by these forward-looking
statements. In particular, the expectations of Valneva could be
affected by, among other things, uncertainties involved in the
development and manufacture of vaccines, unexpected clinical trial
results, regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, the ability to obtain or maintain patent or other
proprietary intellectual property protection, the cancellation of
existing contracts, including but not limited to the VLA2001 supply
agreement with the UK government, and the impact of the COVID-19
pandemic, the occurrence of any of which could substantially harm
Valneva’s business, financial condition, prospects and results of
operations. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in this press release as of the date hereof and
disclaims any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
1 Valneva Receives Conditional Marketing Authorization from UK
MHRA for its Inactivated COVID-19 Vaccine – Valneva2 EMA accepts
filing of marketing authorization application for Valneva’s
inactivated COVID-19 Vaccine Candidate – Valneva3 Valneva
Successfully Completes Pivotal Phase 3 Trial of Single-Shot
Chikungunya Vaccine Candidate – Valneva4 Valneva Successfully
Completes Lot-to-Lot Consistency Trial for its Single-Shot
Chikungunya Vaccine Candidate – Valneva5 Valneva and Pfizer Report
Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
– Valneva
- 2022_06_03_VLA_Jefferies_Conference_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024